We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Partners to Develop and Commercialize New Cancer Therapeutic Drugs

By LabMedica International staff writers
Posted on 21 Feb 2016
German and French biopharmaceutical companies have agreed to cooperate in the development and commercialization of new cancer therapeutics based on drugs that eliminate cancer cells by activating the TLR3 (Toll-like receptor 3) pathway.

Riboxx Pharmaceuticals (Radebeul, Germany) a biotech company developing Toll-like receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and Tollys SAS (Lyon, France), a biotech company developing new cancer therapeutic strategies, have signed a license agreement. More...
The agreement grants Tollys exclusive global development and commercialization rights to the new APOXXIM drug development program.

TLR3 is a member of the Toll-like receptor (TLR) family, which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. RIG-I-like receptors are a type of intracellular pattern recognition receptor involved in the recognition of viruses by the innate immune system.

APOXXIM is a TLR3-ligand that eliminates cancer cells by activating the TLR3 pathway. It displays unique physical, chemical, and biological properties, with increased stability to degradation in body fluids such as human plasma. APOXXIM is manufactured according to Riboxx's unique, patented cGMP TENPORA Process.

Under the terms of the license agreement, Tollys will assume sole responsibility for global development and commercialization of APOXXIM. Riboxx will be responsible for manufacturing and supplying APOXXIM to Tollys.

Jacques Rohayem, CEO and CSO of Riboxx Pharmaceuticals said, "We are very thrilled to start this collaboration with Tollys, a company with a very strong scientific expertise in cancer therapy. This collaboration expands the portfolio of Riboxx drug development programs such as RIBOXXIM, RIBOXXOL and QUADROXXIM, mainly focusing on cancer immunotherapy."

Jacques-François Martin, president of Tollys, said, "Tollys is very pleased to start this collaboration towards the development of a new and unique therapeutic strategy in cancer. The potential of TLR3-ligands such as APOXXIM to treat cancer has been extensively studied in the past decades by scientists at Tollys, with a particular focus on TLR3-positive cancers."

Related Links:

Riboxx Pharmaceuticals



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.